Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

NJ sues Pfizer and others for water contamination

By Julia Rock-Torcivia | October 1, 2025

New Jersey’s Department of Environmental Protection (DEP) has filed a lawsuit against Pfizer, Johnson & Johnson, Honeywell and several real estate companies, claiming there is toxic waste on an old pharmaceutical plant site, contaminating the groundwater. 

The plant, located in Morris Plains, was operational from the 1950s to the 1980s under Warner-Lambert, which Pfizer acquired in 2000. The state claimed the other defendants were “knowing purchasers” of parts of the site. Under New Jersey’s Spill Act, passed in 1976, these companies can be held liable for cleanup if they bought the land with knowledge of the contamination. 

The state is requesting financial compensation for past and future cleanup of the site. There was no specific number stated. The claim alleges that the plant discharged trichloroethylene (TCE), a carcinogen, as well as other hazardous chemicals, contaminating the groundwater. 

In 2012, the site was designated as a classification exception area (CEA), signifying that state groundwater quality standards were not being met and barring the water for drinking or other use. When the site was established as a CEA, the groundwater had a concentration of TCE equal to 5.95 micrograms per liter. The state’s standard is 1 microgram per liter. 

Pfizer spokesman Steven Danehy said in a statement that the company had “a long-standing commitment to protecting the environment,” and that the company was “looking forward” to resolving the allegations. 

Two lawsuit veterans 

As this arises, Pfizer is currently engaged in two other lawsuits. One by the Texas Attorney General Ken Paxton for misleading the public about the efficacy of the COVID vaccine, and the other a multidistrict litigation for failing to warn about the link between Depo-Provera, a contraceptive, and brain tumors. 

NJ Pharma lawsuit settlements

This is not the first time New Jersey has sued big pharmaceutical companies. In 2023, the state reached a $393 million settlement with Solvay for PFAS contamination. This summer, NJ made a settlement with DuPont for $2 billion, also for PFAS, the state’s largest ever settlement for ‘forever chemicals’. In May, 3M agreed to pay up to $450 million to the state for contamination from PFAS, which had been occurring for decades. New Jersey is a veteran in this space, and the most recent suit could be another big payout for the state. 

 

As the plant is no longer operational, the impact of the suit on Pfizer will likely be minimal. It will likely be a few years before any kind of result or settlement is reached.


Filed Under: Biologics
Tagged With: carcinogen, covid vaccine, environment, forever chemicals, J&J, Johnson & Johnson, PFAS, Pfizer, tce, toxic waste
 

Related Articles Read More >

From cost advantage to value advantage: The next frontier for generic manufacturers
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Lilly’s retatrutide shows 28.3% weight loss, but increased side effects
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE